The efficacy of bromfenac ophthalmic solution 0.07% dosed once daily in achieving zero-to-trace anterior chamber cell severity following cataract surgery

Figures & data

Table 1 Ocular inflammation grading scale

Anterior chamber cells		Anterior chamber flare
Grade	Cell count	Grade	Flare count
0	0	0	Complete absence
0.5	1–5 cells (trace)	–	–
1	6–15	1	Very slight (barely detectable)
2	16–25	2	Moderate (iris and lens clear)
3	26–50	3	Marked (iris and lens hazy)
4	>50	4	Intense (fibrin clot)

Table 2 Subject completion

Parameter	Bromfenac 0.07%, n (%)	Placebo, n (%)
Overall study completion	213/222 (95.9%)	202/218 (92.7%)
Full treatment (16 doses) received	143/222 (64.4%)	100/218 (45.8%)a
Percent compliance	91.2%	75.9%b

a Notes: This was statistically significant (P=0.0001);

b this was statistically significant (P<0.0001).

Figure 1 Trace anterior chamber cells (cell count ≤5) at each visit day.

Notes: *P-values statistically significant; days 8 and 15, P<0.0001; day 3, P<0.0007.

Figure 2 Transformed anterior chamber cell grade at each study visit.

Notes: Transformed anterior chamber cell grade was transformed as follows: 0=0, 0.5=1, 1=2, 2=3, 3=4 and 4=5. P-value for bromfenac versus placebo for continuous score was derived from a Student’s t-test, adjusted for multiple comparisons using Hochberg’s method. *P<0.0001.

Figure 3 Severity of anterior chamber cell scores.

Note: *P<0.001.

Figure 4 Mean transformed summed ocular inflammation score.

Notes: Transformed anterior chamber cell grade was transformed as follows: 0=0, 0.5=1, 1=2, 2=3, 3=4 and 4=5. P-value for bromfenac versus placebo for continuous score was derived from a Student’s t-test, adjusted for multiple comparisons using Hochberg’s method. Transformed summed ocular inflammation score is the sum of the flare and transformed cell grades. *P<0.0001.